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Abstract: Alzheimer’s disease is associated with the aggregation of the amyloid-β peptide (Aβ), 
resulting in the deposition of amyloid plaques in brain tissue. Recent scrutiny of the mechanisms by 
which Aβ aggregates induce neuronal dysfunction has highlighted the importance of the Aβ 
oligomers of this protein fragment. Because of the transient and heterogeneous nature of these 
oligomers, however, it has been challenging to investigate the detailed mechanisms by which these 
species exert cytotoxicity. To address this problem, we demonstrate here the use of rationally 
designed single-domain antibodies (DesAbs) to characterize the structure–toxicity relationship of 
Aβ oligomers. For this purpose, we use Zn2+-stabilized oligomers of the 40-residue form of Aβ (Aβ40) 
as models of brain Aβ oligomers and two single-domain antibodies (DesAb18-24 and DesAb34-40), 
designed to bind to epitopes at residues 18–24 and 34–40 of Aβ40, respectively. We found that the 
DesAbs induce a change in structure of the Zn2+-stabilized Aβ40 oligomers, generating a 
simultaneous increase in their size and solvent-exposed hydrophobicity. We then observed that 
these increments in both the size and hydrophobicity of the oligomers neutralize each other in terms 
of their effects on cytotoxicity, as predicted by a recently proposed general structure–toxicity 
relationship, and observed experimentally. These results illustrate the use of the DesAbs as research 
tools to investigate the biophysical and cytotoxicity properties of Aβ oligomers. 
Keywords: protein misfolded oligomers; structure–toxicity relationship; rationally designed 
antibodies; research tools; biophysics; amyloid-β; Alzheimer’s disease 
 
1. Introduction 
The development and progression of Alzheimer’s disease (AD) is characterized by the 
misfolding and aggregation of the amyloid-β peptide (Aβ), which eventually results in the formation 
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of dense senile plaques rich in fibrillar Aβ aggregates [1–3]. Increasing evidence suggests that the 
oligomeric aggregates which form as intermediates during the Aβ deposition process, rather than 
mature fibrils, are the predominant species capable of inducing neuronal dysfunction [4–7]. Targeting 
the rates of formation or the physicochemical properties of Aβ oligomers, therefore, represents one 
of the most promising therapeutic approaches to the treatment of AD [8,9].  
Intense focus on inhibiting Aβ deposition has resulted in the characterization of numerous 
molecules, including small molecules, antibodies and molecular chaperones, which are able to 
prevent Aβ aggregation, and therefore, reduce the rate of Aβ oligomer formation, although no 
disease-modifying compound has yet been approved for clinical use [10,11]. These failures are, in 
part, attributable to the inclusion in clinical trials of participants without Aβ-related pathologies, thus 
confounding the analysis, and of participants with advanced AD, when the amyloid burden has 
already reached an advanced stage, making potential drugs against Aβ-induced neuronal damage 
less effective [12–14]. They are also a consequence of poor quantitative endpoints regarding the 
impact of candidate inhibitors on the microscopic steps governing Aβ aggregation, including the 
number of the highly cytotoxic oligomeric species produced in the presence of potential therapeutics 
[15–21], as well as an incomplete mechanistic understanding of the impact of candidate compounds 
on the physicochemical properties of oligomeric species and their closely related ability to induce 
cytotoxicity.  
Given the advantages of using antibodies as research tools [22,23], in particular for their very 
high selectivity for a specific target (e.g., epitopes on the surface of Aβ oligomers) [18,24,25], in 
addition to reports that have illustrated the efficacy of anti-Aβ immunotherapies [9,26] and the 
potential of anti-Aβ antibodies for early diagnosis [27,28], we recently focused on the development 
of rationally designed antibodies to inhibit the aggregation of Aβ through the selective targeting of 
specific microscopic steps inherent to its self-assembly and propagation [18]. Of particular note, we 
previously found that the designed single-domain antibody raised against residues 18–24 of Aβ 
(DesAb18-24) is a potent inhibitor of the microscopic step of primary nucleation of the Aβ42 amyloid 
fibril formation process. Moreover, its administration to a C. elegans model of AD was shown to 
reduce the toxicity implicit to Aβ42 aggregation when administered before or during the development 
of a pathological phenotype [18]. In light of these observations, and to contribute new tools with 
which to study the impact of candidate therapeutic compounds on the physicochemical properties of 
intermediate oligomeric species, we sought to assess the impact of this and a second rationally 
designed single-domain antibody raised against residues 34–40 of Aβ40 (DesAb34-40) on stabilized 
cytotoxic oligomeric species of Aβ40 after their formation, which were generated from both primary 
and secondary nucleation pathways in the endogenous Aβ aggregation reaction [19].  
To investigate the relationship between the structure and the toxicity of Aβ40 oligomers, we first 
determined the effects of DesAb18-24 and DesAb34-40 on the in vitro aggregation of Aβ40. Then, we 
analyzed the effects of these DesAbs on the size and hydrophobicity of Zn2+-stabilized Aβ40 oligomers 
formed under near physiological conditions. We found that the DesAbs induced the formation of 
larger and more hydrophobic Aβ40 oligomers. As a control, we then showed that the natural product 
trodusquemine, which protects cell membranes from the cytotoxic effects of protein misfolded 
oligomers at substoichiometric concentrations [29], induces similar effects to these DesAbs when 
used at concentrations that are superstoichiometric and higher than those normally used in cells or 
patients due to its intrinsic toxicity. Increases in size and hydrophobicity are known to cause a 
decrease and increase of oligomer toxicity, respectively [30–36]. In fact, consistent with previous 
quantifications of the size–hydrophobicity relationship modulated by mutations on another protein 
system [30], we observed that these effects mediated by our DesAbs on Aβ40 did not significantly 
change the degree of cytotoxicity of the oligomers towards SH-SY5Y neuroblastoma cells, indicating 
that the simultaneous increase in oligomer size and hydrophobicity produces antagonistic effects on 
oligomer toxicity. 
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2. Results 
2.1. The DesAbs Inhibit Aβ40 Aggregation 
In this work, we investigate two computationally-designed, single-domain antibodies, called 
DesAb18-24 and DesAb34-40, which target the regions 18–24 and 34–40 of Aβ40, respectively. These 
antibodies were generated by grafting a complementary peptide into the third complementary 
determining region (CDR3) of a single-domain antibody scaffold, as described previously [18,37].  
We first investigated the effect of these two DesAbs on Aβ40 aggregation. Samples containing 
monomeric Aβ40 at a concentration of 10 µM (20 mM Tris, 100 mM NaCl, pH 7.4) were prepared in 
the absence and presence of 20-, 10-, and 5-fold substoichiometric concentrations of the designed 
antibodies and incubated under quiescent conditions at 37 °C. The fibrilization process was 
monitored by means of thioflavin T fluorescence (ThT) in the presence of 20 µM ThT. We observed 
that DesAb18-24 strongly inhibits Aβ40 aggregation, causing a significant delay in the half-time of 
aggregation (t1/2) (Figure 1a), which is in agreement with previous findings for Aβ42 [18]. Indeed, at 
the highest concentration of DesAb18-24 (2 µM), Aβ40 did not aggregate beyond t1/2 in this experiment 
on the time course of 25 h. Further experiments on DesAb34-40 revealed that this designed antibody 
was also able to interfere with the reaction, as observed by an overall delay in the aggregation kinetics 
(Figure 1b). Interestingly, both DesAbs inhibited the aggregation kinetics in a concentration-
dependent manner, as illustrated by the relative changes in t1/2 (Figure 1c). Experiments were carried 
out in triplicate, and indicated that both designed antibodies can significantly delay Aβ40 aggregation.  
 
Figure 1. DesAb18-24 and DesAb34-40 inhibit Aβ40 aggregation. (a,b) Thioflavin T (ThT) fluorescence 
intensity profiles for the aggregation of Aβ40 (10 μM) incubated in the absence (black) and presence of 
0.5 μM (yellow), 1 μM (orange) and 2 μM (red) DesAb18-24 (a) and DesAb34-40 (b). Upward error bars 
indicate standard error of the mean (SEM) of three technical replicates. (c) Relative change in half-
time (t1/2) calculated from dividing t1/2 for each experimental condition by the average t1/2 determined 
for Aβ40 in the absence of DesAbs to show the relative delay in aggregation induced by the antibodies. 
Error bars indicate SEM of three technical replicates. Individual antibody groups were analyzed by 
one-way ANOVA followed by a Bonferroni’s multiple comparison test relative to Aβ40 in buffer. The 
symbols *, **, and **** indicate p < 0.05, 0.01 and 0.0001, respectively. 
2.2. The DesAbs Bind Stabilized Aβ40 Oligomers and Increase Their Hydrophobic Surface Area 
During the aggregation of Aβ40 at the concentrations used here, the peak oligomer concentration 
reached circa 1% of the total monomer concentration at the half-point of the aggregation reaction 
[21,38]. Given the very low abundance and high instability of on-pathway oligomers, numerous 
methods have been described to generate and stabilize oligomers at concentrations that are orders of 
magnitude higher [39–42]. For this purpose, oligomers of Aβ40 stabilized by Zn2+ were produced as 
previously described [42]. These oligomers are stabilized by a metal ion that is naturally present at 
the synapse, and may therefore resemble those that exist in AD [42]. 
We first tested the ability of these antibodies to bind to stabilized Aβ40 oligomers using a dot-
blot assay (Supplementary Figure 1). Then, we evaluated the degree of hydrophobicity of the 
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oligomers in the absence and presence of the DesAbs using the fluorescent dye 8-anilinonapthalene-
1-sulfonic acid (ANS), which binds to hydrophobic patches on the surfaces of protein aggregates, 
generating a quantum yield increase and blue shift of fluorescence relative to unbound dye [43]. We 
incubated stabilized Aβ40 oligomers after their formation [42] for 2 h at 20 °C at a concentration of 10 
µM (in monomer equivalents) in 20 mM Tris, 100 mM NaCl and at pH 7.4 in the absence and presence 
of increasing concentrations (0.2 µM, 0.5 µM, 1 µM, and 2 µM) of each antibody. After incubation, 
ANS was added to a final concentration of 30 µM (i.e., 3-fold excess). Similar to our previous 
characterization for Aβ42 oligomers [29], ANS fluorescence intensity was observed to increase and 
undergo a blue-shift from ca. 510 nm to ca. 475 nm in the presence of stabilized Aβ40 oligomers. 
Incubation in the presence of increasing concentrations of DesAb18-24 and DesAb34-40 resulted in the 
amplification of this effect with a clear, well-defined dose dependence (Figure 2a,b). Data were 
quantified by maximum ANS fluorescence intensity (Figure 2c,d). Representative data are shown for 
three independent protein preparations that yielded consistent results. The incubation of 2 µM 
DesAbs (i.e., the highest ratio tested) in the absence of oligomers exerted a negligible effect on ANS 
fluorescence. These results indicate that the hydrophobicity of the Aβ40 oligomers increased as a 
function of antibody concentration.  
 
Figure 2. DesAb18-24 and DesAb34-40 increase the hydrophobic area of stabilized Aβ40 oligomers. ANS 
binding measurements for oligomers of Aβ40 incubated at a concentration of 10 µM in the absence 
(black) or presence of 0.2 μM (green), 0.5 μM (yellow), 1 μM (orange) and 2 μM (red) DesAb18-24 (a) 
and DesAb34-40 (b). The intensity of maximum ANS fluorescence for DesAb18-24 (c) and DesAb34-40 (d), 
determined from the spectra indicated in (a) and (b), respectively. Note that the highest concentration 
of DesAbs tested (2 µM, dark red) did not significantly change the fluorescence of free ANS (grey) in 
the absence of oligomers. Error bars denote SEM of duplicate spectra. Samples containing oligomers 
were analyzed by one-way ANOVA followed by a Bonferroni’s multiple comparison test relative to 
oligomers in buffer. The symbols *, **, and *** indicate p < 0.05, 0.01 and 0.001, respectively. 
2.3. DesAbs Increase the Size of Stabilized Aβ40 Oligomers 
We hypothesized that DesAb18-24 and DesAb34-40 may be able to sequester the aggregates in 
solution via a clustering-based mechanism. This mechanism has been described for molecular 
chaperones in the presence of several oligomeric species comprising various peptides and proteins 
[31–33,35]. To probe this interaction, we first measured the turbidimetry absorbance (turbidity) of the 
same samples that were investigated in the ANS experiment. In parallel with an increase in 
hydrophobicity, we also observed that the spectra were shifted to higher values of turbidity as a 
function of antibody concentration (Figure 3a,b). Data were quantified by integrating the area under 
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gave consistent results. It should be noted that the highest concentration of DesAbs used in our 
experiments absorbed at a level which cannot recapitulate the full effects observed on size in the 
presence of the oligomers, indicating that the antibody exerts a negligible effect on absorbance in the 
absence of oligomers. These results demonstrate that the size of the oligomers increased in a dose-
dependent manner by DesAb18-24 and DesAb34-40. 
In order to validate the increase in size with an ANS-free independent method, samples were 
incubated under the same conditions and measured using static light scattering (SLS). In agreement 
with the turbidity measurements, we found that the incubation of the stabilized oligomers in the 
presence of increasing concentrations of DesAbs resulted in augmented light scattering (Figure 3e,f). 
As additional evidence of a size increase of the aggregates in solution, we also employed 
sedimentation-based dot-blot assays. In these measurements, larger aggregates are postulated to 
sediment more readily than unmodified small oligomers. Oligomers were incubated as previously 
described with and without antibodies, centrifuged (13,000 rcf, 20 °C, 15 min), concentrated during 
resuspension, and deposited atop a nitrocellulose membrane. Minimal protein was deposited in the 
samples containing oligomers in the absence of antibodies, as recognized using the anti-Aβ antibody 
6E10. The presence of the DesAbs, however, resulted in an increase of Aβ40 sedimentation with dose 
dependence (Supplementary Figure 2). Taken together, the turbidimetry, SLS, and sedimentation 
measurements support the conclusion that the DesAbs significantly increase the size of the Aβ40 
oligomers in solution. We note that recent work on oligomers demonstrated that protein misfolded 
oligomer toxicity is independent of their secondary structures [44], and we therefore elected to focus 
on the size–hydrophobicity–toxicity relationship in detail. 
 
Figure 3. DesAb18-24 and DesAb34-40 increase the size of stabilized Aβ40 oligomers. (a,b) Turbidity 
measurements for oligomers of Aβ40 incubated at a concentration of 10 µM in the absence (black) or 
presence of 0.2 μM (green), 0.5 μM (yellow), 1 μM (orange) and 2 μM (red) of DesAb18-24 (a) and 
DesAb34-40 (b). Samples are identical to those shown in Figure 2. (c,d). Turbidity traces analyzed by 
area under the curve integration. Note that the highest concentration of DesAbs tested (2 µM, dark 
red) did not significantly change the absorbance relative to the blank (ANS, grey). Error bars denote 
SEM of duplicate spectra. (e,f) SLS measurements in the absence of ANS and the presence of Aβ40 
oligomers and increasing concentrations of the designed antibodies. Note negligible scattering from 
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measurements. In all panels, the symbols *, **, *** and **** indicate p < 0.05, 0.01, 0.001 and 0.0001, 
respectively. Samples containing oligomers were analyzed by one-way ANOVA followed by 
Bonferroni’s multiple comparison test relative to oligomers in buffer. 
To directly visualize the size and morphology of these oligomer clusters, we next investigated 
the oligomer-DesAb34-40 complex by phase-controlled atomic force microscopy (AFM) [45,46]. 
Stabilized Aβ40 oligomers were incubated as previously described at a concentration of 10 µM (in 
monomer equivalents) in the absence and presence of 2 µM DesAb34-40 (2 h, 20 °C), and diluted in 
buffer by a factor of 20 before conventional, manual deposition atop an atomically flat mica surface. 
In the absence of DesAb34-40, oligomers were 1–5 nm in height (Figure 4), in agreement with previous 
characterizations [42]. In the presence of DesAb34-40, clusters ranging in cross-sectional height from 20 
to 50 nm were readily observed, in good agreement with the size results observed in the bulk 
experiments (Figure 4). 
 
Figure 4. Phase-controlled AFM measurements of the oligomer-antibody complexes. Aβ40 oligomers 
were incubated at a concentration of 10 µM in the absence (left) and presence of 2 µM DesAb34-40 
(right) and diluted 20-fold in buffer before deposition. Large oligomeric clusters (white aggregates in 
the 3D AFM maps) were observed in the presence of DesAb34-40. Representative aggregate heights are 
shown below each 3D color plot for the indicated cross-sectional profiles. Scale bars, 0.2 µm. 
2.4. Trodusquemine Binds Stabilized Aβ40 Oligomers and Increases their Hydrophobic Surface Area 
The natural product trodusquemine has been characterized for its ability to displace protein 
misfolded oligomers from the surfaces of cell membranes, resulting in a marked decrease in oligomer-
induced cytotoxicity towards neuroblastoma cells. Its protective effects were observed at 
physiological concentrations of this aminosterol, corresponding to equimolar or substoichiometric 
concentrations of the molecule relative to oligomers, where greater than equimolar concentrations of 
trodusquemine demonstrated its intrinsic toxicity to cells [29]. Further, we previously observed that 
trodusquemine can increase the size and hydrophobicity of Aβ42 oligomers at superstoichiometric 
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To build on this result and to increase the size and hydrophobicity of Aβ40 oligomers similarly 
to our DesAbs, and thus to obtain a control case for this study, we incubated stabilized Aβ40 oligomers 
at a concentration of 5 µM (in monomer equivalents) in 20 mM Tris, 100 mM NaCl, pH 7.4, in the 
absence and presence of increasing concentrations of trodusquemine (0–50 µM, 1 h at 20 °C). After 
incubation, ANS was added to a final concentration of 15 µM (i.e., 3-fold excess). The incubation of 
Aβ40 oligomers with trodusquemine increased the maximum fluorescence intensity and caused a 
further blue-shift of its wavelength, with a well-defined dose dependence (Figure 5a), indicating a 
prominent increase in solvent-exposed hydrophobicity. As a control, both the intensity and 
maximum wavelength of free ANS were unchanged in the absence of oligomers and in the presence 
of the highest concentration of trodusquemine (i.e., 50 µM).  
The incubation of stabilized Aβ40 oligomers with trodusquemine and ANS also resulted in a 
well-defined increase in turbidity with a clear dose dependence (Figure 5b). Using SLS measurements 
in the absence of ANS, we also observed a dose-dependent increase in the extent of light scattered 
upon the incubation of the oligomers in the presence of increasing concentrations of trodusquemine 
(Figure 5c). Negligible turbidity and light scattering were measured for 50 µM trodusquemine in the 
absence of oligomers (Figure 5b,c), indicating that the molecule does not form large clusters under 
these conditions, and does not contribute significantly to the observations in the presence of Aβ40 
oligomers. The relative change in the extent of light scattered upon the interaction of increasing 
concentrations of trodusquemine with the oligomers is in good agreement with the turbidity data.  
 
Figure 5. Trodusquemine increases the hydrophobicity and size of stabilized Aβ40 oligomers. (a,b) 
Oligomers were incubated at a concentration of 5 µM in the absence (black) and presence of 5 µM 
(green), 12.5 µM (yellow), 25 µM (orange), 37.5 µM (red), and 50 µM (brown) trodusquemine and 
monitored for the binding of ANS (a) and turbidity absorbance (b). Grey traces indicate the effect of 
50 µM trodusquemine (TRO) (i.e., the highest ratio tested) in the absence of oligomers. Error bars 
denote SEM of duplicate spectra. (c) SLS measurements after oligomer incubation in the presence of 
increasing concentrations of trodusquemine. Data are shown as the change in light scattered. Error 
bars represent the SEM of three replicates, and the symbols ** and *** indicate p < 0.01 and 0.001, 
respectively. Samples containing oligomers were analyzed by one-way ANOVA followed by 
Bonferroni’s multiple comparison test relative to oligomers in buffer. (d) AFM maps for oligomers 
incubated in the absence (left panel) or presence of a 5-fold excesses of trodusquemine (right panel). 
Scale bars, 2 µm. Upper limits on the color scales are circa 4.2 nm for Aβ40 oligomers alone (left panel) 
and 35 nm for the Aβ40 oligomer-trodusquemine complex (right panel). (e) Representative cross-
sectional heights of oligomers in the absence (left panel) and presence of trodusquemine (right panel). 
Dotted white lines in indicate the corresponding sampled cross section from d. 
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The trodusquemine-mediated modification of stabilized Aβ40 oligomers was also studied using 
phase-controlled AFM [45,47,48]. Sample deposition was carried out using a recently developed 
microfluidic spraying device [49]. The utilization of this methodology affords the advantage of 
spraying microdroplets atop the mica substrate at subpicoliter volumes, which evaporate on the 
timescale of milliseconds, thereby avoiding artefacts due to surface mass transport processes caused 
by drying [49], which are particularly likely while drying significant concentrations of a polyvalent 
small molecule in addition to oligomers. Stabilized Aβ40 oligomers were incubated as previously 
described at a concentration of 5 µM in the absence and presence of a 5-fold excess of trodusquemine 
(1 h, 20 °C) and subsequently diluted by a factor of five in buffer prior to spraying atop an atomically 
flat mica surface (Figure 5d). In the absence of molecules, the cross-sectional heights of the oligomers 
were typically 1–5 nm in height, in agreement with previous reports [42]. Upon the addition of a 5-
fold excess of molecule, the presence of large clustered species was observed with cross-sectional 
heights ranging from approximately 20 to 40 nm (Figure 5e), in good agreement with the turbidity 
and SLS results observed in the bulk experiments. 
2.5. The DesAbs Do Not Change the Toxicity of Aβ40 Oligomers for Human Neuroblastoma Cells 
To assess whether the increase in oligomer size and hydrophobicity induced by DesAbs and 
trodusquemine resulted in changes of oligomer toxicity, cell viability experiments using the MTT 
reduction assay were performed using SH-SY5Y human neuroblastoma cells in the presence of the 
oligomers. Stabilized Aβ40 oligomers (5 µM, in monomer equivalents) were formed and incubated in 
the absence and presence of increasing concentrations of DesAb18-24 and DesAb34-40 (0.25 µM, 0.5 µM 
and 1 µM) for 1 h at 37 °C, and subsequently added to the cell culture medium of SH-SY5Y cells for 
24 h at 37 °C. These concentrations were selected to match the biophysical experiments. The cells 
were also treated with the corresponding concentrations of antibodies in the absence of oligomers, 
which was not observed to induce deleterious changes in cellular viability. Aβ40 oligomers were 
found to decrease the viability of the cells by 23.4 ± 3.6%, and this toxicity was not changed 
significantly upon the addition of either DesAb when co-incubated with oligomers at these 
concentrations (Figure 6a). 
 
Figure 6. The interaction of the DesAbs with stabilized Aβ40 oligomers does not change their toxicity. 
(a) Stabilized oligomers of Aβ40 were resuspended in the cell culture medium at a concentration of 5 
μM and incubated in the absence (black plain bar) or presence of increasing concentrations (0.25, 0.5 
and 1 µM) of DesAb18-24 (red plain bars) and DesAb34-40 (blue plain bars) for 1 h at 37 °C and then 
added to the cell culture medium of SH-SY5Y cells for 24 h. The cells were also treated with 
corresponding concentrations of the antibodies pre-incubated in the absence of oligomers (dashed 
bars with corresponding colors). Error bars indicate SEM of six replicates. The symbol *** indicates p 
< 0.001 (unpaired, two-tailed Student’s t-test). All conditions containing both antibodies and 
oligomers were not significantly different in comparison to cells treated with oligomers alone 
(individual antibody groups were compared by one-way ANOVA using Bonferroni’s multiple 
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fluorescence as a probe of solvent exposed hydrophobicity and the Rayleigh ratios from SLS 
measurements as a measure of size were used to predict the change in MTT reduction caused by 
oligomers in the absence and presence of the various concentrations of DesAbs (Supplementary Table 
1) as previously described [30]. The predicted values were plotted against the observed ones from (a). 
The formula predicts that the DesAb-mediated increase in both hydrophobicity and size of Aβ40 
oligomers does not significantly change the toxicity, as was observed experimentally. 
We then compared the observed experimental changes in cell viability upon the addition of 
various concentrations of DesAbs to Aβ40 oligomers to the predicted changes, where the latter was 
estimated using a previously defined formula [30] (Figure 6b, Supplementary Table 1). The 
comparison indicated that the toxicity of stabilized Aβ40 oligomers was neither predicted nor 
observed to change upon the addition of these concentrations of DesAb18-24 and DesAb34-40. This might 
appear surprising, as oligomer size and hydrophobicity are known to be key determinants of 
oligomer toxicity [30–36]. However, increases in size and hydrophobicity are predicted to decrease 
and increase oligomer toxicity, respectively, resulting in counteracting effects and no overall change 
in toxicity. The highly significant correlations found between Aβ40 oligomer size and hydrophobicity 
in the presence of designed antibodies and trodusquemine indicate that these agents cause paired 
increases of both parameters (Figure 7), resulting in no significant effect on the toxicity of the Aβ40 
oligomers (Supplementary Table 1). 
 
Figure 7. Size-hydrophobicity relationship for increasing concentrations of the designed antibodies 
and trodusquemine. (a) Linear fits between size and solvent-exposed hydrophobicity for increasing 
concentrations of DesAb34-40 (blue line, slope = 0.84 ± 0.15, R = 0.95), DesAb18-24 (red, slope = 0.38 ± 0.08, 
R = 0.86), and trodusquemine (TRO, black line, slope = 0.39 ± 0.12, R = 0.86). (b) Zoomed in view of 
panel a for the designed antibodies. 
We also measured the toxicity of the oligomers with a greater concentration (i.e., 10 µM, 
monomer equivalents) and at the same molar ratios studied above, i.e., 0.5 µM, 1 µM and 2 µM 
antibodies (Supplementary Figure 3). Again, the addition of DesAb18-24 did not alter the toxicity of the 
stabilized Aβ40 oligomers, suggesting that the concentration of toxic species is not likely to result in 
different biological activity of the antibodies. Collectively, these results suggest that the ability of the 
antibodies to cluster the oligomers into larger and more hydrophobic species does not change the 
toxicity of the aggregates, which agrees well with the predictions (Supplementary Table 1).  
It was not possible to carry out the MTT assays for Aβ40 oligomers incubated with 
trodusquemine at the superstoichiometric concentrations that are necessary to observe a significant 
clustering effect of the oligomers [29]. Indeed, the molecule alone was shown to be toxic to cells at 
concentrations greater than a few micromolar [29]. Such an experiment would further fail to account 
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3. Discussion 
Aβ oligomers are highly cytotoxic species associated with the aggregation reaction of Aβ, which 
is central to the onset and development of AD [4–7]. Extensive past work has been carried out to 
investigate the structure-toxicity relationship of these oligomers, for example through the use of 
cross-linking to generate stabilized oligomeric forms [50–52]. More specifically, the toxicity of 
aberrant oligomeric protein aggregates has been previously described as a function of size and 
hydrophobicity for multiple proteins, where the most cytotoxic aggregates are generally small and 
have extensive hydrophobic surface exposure [30,32,35]. These physiochemical properties play a 
central role in the ability of oligomers to cause cellular dysfunction, which can result from the uptake 
of the oligomeric proteins into the cell [53–55], or directly by the oligomer-induced perturbation of 
cell membranes [3,36]. Here, we utilized rationally designed antibodies (DesAbs) to probe the 
structure–toxicity relationship of Zn2+-stabilized Aβ40 oligomers, which we adopted as models of the 
Aβ oligomers that may form in synaptic regions where Zn2+ tends to be abundant [42]. We used these 
DesAbs as molecular tools, following our previous illustrations of their applications for diagnostic 
[27] or therapeutic purposes [18].  
An increase in size alone, in the absence of other physicochemical changes, has been well 
documented to suppress oligomer cytotoxicity. Indeed, high concentrations of molecular chaperones, 
including clusterin and aβ-crystallin, have been shown to reduce the cellular toxicity of oligomers 
comprised of Aβ42, HypF-N, and islet amyloid polypeptide through a clustering-based mechanism 
[31,33,35]. The reduction in toxicity mediated by clustering was therefore attributed to a prominent 
decrease in the surface to volume ratio of the aggregates, thereby reducing the diffusibility of the 
oligomers and limiting their interaction with the cellular membrane [32,35]. In the case of the DesAb18-
24 and DesAb34-40, and trodusquemine at superstoichiometric concentrations, Aβ40 oligomer size was 
significantly increased upon interaction with the antibodies and the aminosterol. 
In addition to size, hydrophobicity is a key determinant of oligomer cytotoxicity [34,36]. A 
decrease in hydrophobicity is associated with lower cytotoxicity. At superstoichiometric 
concentrations of clusterin and aβ-crystallin relative to HypF-N oligomers, these molecular 
chaperones were shown to be able to mask the solvent exposure of protein misfolded oligomers in 
the absence of significant oligomer size increases [32,35]. The corresponding decrease in cellular 
toxicity was explained by their lessened affinity for cell membranes induced by the lowering of 
oligomer solvent-exposed hydrophobicity. For DesAb18-24 and DesAb34-40 and trodusquemine at 
superstoichiometric concentrations, however, Aβ40 oligomer hydrophobicity was significantly 
increased upon interaction with the antibodies and molecules.  
The DesAbs modified the structure of the oligomers in a way that is expected to increase their 
cytotoxicity by increasing their hydrophobicity. At the same time, the DesAbs could also be expected 
to decrease the toxicity of the oligomers by increasing their size. Thus, by using the DesAbs as 
molecular tools, we leveraged a well-described size–hydrophobicity formula [30] to predict that these 
physiochemical changes would cancel each other in terms of the resulting toxicity of the oligomers. 
Experimentally, we confirmed these predictions by observing that these changes offset each other, as 
manifested by negligible changes in oligomer toxicity to the neuroblastoma cells upon interaction 
with the DesAbs (Figure 8).  
Trodusquemine and other molecules within the aminosterol family possess the unique ability to 
bind to cell membranes and prevent the deleterious association of oligomers via a displacement-
based mechanism [29,56,57]. Given the absence of a protective effect of the DesAbs toward 
neuroblastoma cells when incubated alongside oligomers at the substoichiometric concentrations 
employed herein and as expected for a large antibody, they likely do not bind to cell membranes or 
displace protein misfolded oligomers. Moreover, the increases in both hydrophobicity and size 
induced by superstoichiometric concentrations of trodusquemine would be expected not to 
significantly change the cytotoxicity of the aggregates in the absence of the trodusquemine-induced 
displacement of oligomers; such an experiment could not be carried out given the intrinsic toxicity of 
trodusquemine at the concentrations necessary to observe these nonphysiologically relevant 
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physiochemical changes [29]. Nonetheless, these findings show that the phenomena described herein 
extend beyond DesAb18-24 and DesAb34-40 to small molecules.  
 
Figure 8. We have used rationally designed antibodies (DesAbs) as molecular tools to investigate the 
size-hydrophobicity-toxicity relationship of Aβ40 oligomers. Incubation with DesAbs increased the 
size and hydrophobicity of Zn2+-stabilized Aβ40 oligomers. These physicochemical changes decrease 
and increase the toxicity of these particular model oligomers, respectively, resulting in no net overall 
change in their toxicity upon administration to cultured human neuroblastoma cells. 
Based on these results, we anticipate that it may become possible in future systematic studies to 
obtain more insights into the structure-toxicity relationship of oligomers with new DesAbs targeting 
disease-related proteins. Utilization of in vitro assays capable of predicting the toxicity of oligomers 
by probing their structural and physicochemical properties could facilitate enhanced throughput 
preclinical drug discovery studies by limiting in part the need of more expensive and time-
consuming cell culture experiments. 
4. Materials and Methods  
4.1. Chemicals 
Trodusquemine was synthesized as a hydrochloride salt at a purity greater than 97%, stored as 
a lyophilized powder [58,59] and solubilized in water to a final concentration of 10 mM. Stocks were 
stored at –20 °C until use. 
4.2. Antibody Design, Expression and Purification 
Antibodies were computationally designed as previously described [18,37]. Complementary 
peptides designed to bind specific epitopes were grafted onto the CDR loops of domain antibodies 
[18,37]. The expression and purification of the antibodies were carried out as previously described 
[18]. In brief, DesAb constructs were expressed and purified using pRSET-B vector in E. coli Rosetta-
gami 2 (DE3, Merck Millipore, Burlington, MA, USA), cells were grown, harvested and lysed, and 
the antibodies (circa 18 kDa) were purified using a Ni2+-NTA Superflow column (Qiagen, Hilden, 
Germany) [18]. The His-tagged antibodies were eluted by increasing the concentration of imidazole, 
and were subsequently dialyzed thoroughly in PBS. Protein concentration was determined by 
absorbance at 280 nm [18]. DesAb aliquots were stored at –20 °C until use and never thawed more 
than once. The sequence of DesAb18-24 is 
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPKLEVQLVESGGGLVQPGGSLRLSCAASG
FNIKDTYIGWVRRAPGKGEEWVASIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDT
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4.3. Protein Expression and Chemical Kinetics 
The recombinant Aβ(M1-40) peptide (sequence MDAEFRHDSGY EVHHQKLVFF 
AEDVGSNKGA IIGLMVGGVV), denoted as Aβ40, was expressed in the Escherichia coli BL21 Gold 
(DE3) strain (Stratagene, San Diego, CA, USA) and purified as described previously [19]. Samples for 
kinetic experiments were prepared using standard reagents and methods with a final buffer 
composition of 20 mM Tris, 100 mM NaCl, pH 7.4. The concentration of the purified protein was 
quantified as it eluted off the column by integrating the peak area of absorbance with ε280 = 1400 L 
mol-1 cm-1 [60].  
For kinetic experiments, samples were prepared with monomeric Aβ40 at a concentration of 10 
µM in the absence or presence of 0.5 µM, 1 µM, and 2 µM DesAbs. All samples for the kinetic 
measurements were supplemented with 0.2 mM ethylenediaminetetraacetic acid (EDTA) [29]. ThT 
was added from a 2 mM stock to give a final concentration of 20 µM. All samples were prepared in 
low-binding Eppendorf tubes, and samples were analyzed in a 96-well half area, low-binding, clear-
bottom PEG coated plate (Corning 3881, Sigma-Aldrich, St. Louis, MO, USA). ThT fluorescence was 
monitored in triplicate per sample and measured using bottom-optics in a plate reader (Fluostar 
Omega or Fluostar Optima from BMG Labtech, Aylesbury, UK) with 440 and 480 nm excitation and 
emission filters, respectively. Aggregation was initiated by transferring the 96-well plate to the plate 
reader at 37 °C under quiescent conditions. The data shown are representative of three independent 
experiments that gave consistent results. 
4.4. Preparation of the Stabilized Aβ40 Oligomers 
First, 1 mg of lyophilized Aβ40 was solubilized overnight in 300 µL hexafluoroisopropanol 
(HFIP) at 4 °C. Solvent was evaporated with a gentle flow of nitrogen gas, and the protein was 
resuspended in DMSO to 2.2 mM. Two sonication steps of 10 min were preformed, after which the 
protein was diluted at a concentration of 100 µM in 20 mM sodium phosphate buffer, 200 μM ZnCl2, 
pH 6.9 for 20 h at 20 °C. Samples were centrifuged (15,000 rcf, 20 °C, 15 min) to a pellet and the 
supernatant was removed [42]. Oligomers were resuspended in buffer (20 mM Tris, 100 mM NaCl, 
pH 7.4) with thorough mixing.  
4.5. ANS Binding Measurements  
First, 10 µM Aβ40 oligomers (monomer equivalents) were incubated (2 h, 20 °C) in the absence 
and presence of increasing concentrations of DesAbs (20 mM Tris, 100 mM NaCl, pH 7.4) at. Samples 
containing trodusquemine were incubated (1 h, 20 °C) at an oligomer concentration of 5 µM (20 mM 
Tris, 100 mM NaCl, pH 7.4) in the absence or presence of the small molecule at concentrations ranging 
from 5 µM to 50 µM. Subsequently, ANS was added to a final concentration of 30 µM or 15 µM, 
respectively (i.e., 3-fold excess dye in both cases). Emission spectra were recorded using a plate reader 
(BMG Labtech) with excitation at 380 nm. Duplicate samples are representative of three independent 
experiments that gave consistent results. All spectra were background subtracted to the buffer. 
4.6. Turbidimetry Measurements 
Samples from the ANS preparation were analyzed using a plate reader (BMG Labtech) with 
spectral scanning. Duplicate samples are representative of three independent experiments that gave 
consistent results. All spectra were background subtracted to the buffer. 
4.7. SLS 
First, 10 µM Aβ40 oligomers (monomer equivalents) were incubated for 2 h in the absence and 
presence of increasing concentrations of DesAbs (20 mM Tris, 100 mM NaCl, pH 7.4) at 20 °C. SLS 
measurements were performed using the Malvern Zetasizer Nano S instrument (Malvern Panalytical, 
Malvern, UK) with fixed parameters (attenuator 9, cell position 4.65 mm), equipped with a Peltier 
temperature controller (25 °C). A low volume (70 µL) disposable cuvette was used (BrandTech 
Scientific, Essex, CT, USA). Samples containing trodusquemine were incubated (1 h, 20 °C) at an 
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oligomer concentration of 5 µM (20 mM Tris, 100 mM NaCl, pH 7.4) in the absence or presence of the 
small molecule at concentrations ranging from 5 µM to 50 µM. 
4.8. Sedimentataion-Based Dot Blot Assays 
Aβ40 oligomers were prepared at a concentration of 10 µM (monomer equivalents) and incubated 
in the absence or presence of 0.5, 1.0 and 2 µM DesAbs, as described above. For sedimentation 
measurements, 50 µL aliquots of samples were centrifuged (Eppendorf Centrifuge 5424 R, Hambrug, 
Germany) for 10 min at 13,000× g and 20 °C. Supernatant was removed and protein was thoroughly 
resuspended in 20 µL buffer prior to spotting the nitrocellulose membrane (2 µL per spot) (Whatman, 
pore size of 0.2 µm, GE Healthcare). Membranes were blocked with skim milk (Sigma-Aldrich) for 1 
h, after which time the primary antibody 6E10 (803001, BioLegend, San Diego, CA, USA) was 
incubated at a 1:1000 dilution overnight at 4 °C. The Alexa488-conjugated secondary antibody (anti-
mouse, Life technologies, Carlsbad, CA, USA) was subsequently incubated for 1 h at a 1:5000 dilution 
at 20 °C. Fluorescence was detected using a Typhoon Trio Imager (GE Healthcare, Chicago, IL, USA). 
Membranes were prepared in duplicate, and representative images are shown. ImageJ was used for 
quantifications. 
4.9. Antibody Binding Dot Blot Assays 
In order to assess the binding of the DesAbs, dot blots were prepared as follows: 4 μM solutions 
of DesAb were spotted (3.5 μL) onto a 0.2 μm pore size nitrocellulose membrane corresponding to 
total deposited antibody of 50, 25, 12.5 and 6.3 µg DesAb. The blots were blocked in PBS, 5% BSA 
overnight at 4 °C. Subsequently, they were incubated in solutions containing 5 μM Aβ40 oligomers in 
PBS overnight at 4 °C. Blots were then probed with the mouse monoclonal anti-amyloid β antibody 
(clone 6E10) (1:2000 dilution; Absolute Antibody Ltd., Oxford, UK) overnight at 4 °C, and then with 
goat anti-mouse IgG (H+L) secondary antibody and AF488 conjugate (1:5,000 dilution; Life 
Technologies) for 2 h at 25 °C.  
4.10. Atomic Force Microscopy  
Aβ40 oligomers (10 µM, monomer equivalents) were incubated in the absence and presence of 2 
µM DesAb34-40, as previously described, and diluted by a factor of 20 before deposition atop an 
atomically flat mica surface. AFM samples preparation was carried out at room temperature by 
deposition of a 10 µL drop of solution deposited for 2 min to a freshly-cleaved mica surface. Salt was 
washed with water, and samples were dried by the gentle flow of nitrogen and stored in a sealed 
container until imaging using a Park NX10 AFM (Park Systems, Suwon, Korea) with scan rates <0.4 
Hz and PPP-NCHR cantilevers with an 8 nm nominal radius (Nanosensors, Neuchatel, Switzerland). 
To visualize the trodusquemine-oligomer complex, Aβ40 oligomers (5 µM, monomer equivalents) 
were incubated in the absence and presence of 25 µM trodusquemine for 1 h as previously described. 
These samples were diluted in buffer by a factor of five and subsequently sprayed at 100 µL/h for 1 
min. at room temperature using a recently described microfluidic device [49] atop an atomically flat 
mica surface. Samples were stored in a sealed container until imaging using a JPK Nanowizard2 AFM 
with scan rates <0.3 Hz and a silicon tip with a 10 nm nominal radius (2 N m-1, MikroMasch, Wetzlar, 
Germany). For all samples, standardized scanning conditions were established and maintained while 
measuring the samples, such that a phase change on the order of ≈Δ20 ° upon the interaction of the 
tip with the sample was not exceeded; changes corresponding to dissipated energy during the 
sample–tip interactions in excess of this threshold can lead to artifacts in the height quantification 
caused by deformations induced in the sample by the tip [29,45,61]. Three-dimensional maps were 
flattened using the SPIP (Image Metrology, Horsholm, Denmark) software, and the cross-sectional 
height of unique aggregates was compared [47,61].  
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4.11. Neuroblastoma Cell Cultures 
Human SH-SY5Y neuroblastoma cells (Sigma-Aldrich, origin from A.T.C.C., Manassas, VA, 
USA) were cultured in DMEM, F-12 HAM with 25 mM HEPES and NaHCO3 (1:1) and supplemented 
with 10% FBS, 1 mM glutamine and 1.0% antibiotics. Cell cultures were maintained in a 5% CO2 
humidified atmosphere at 37 °C, and grown until they reached 80% confluence for a maximum of 20 
passages [62,63]. Cell lines were authenticated, and tested negative for mycoplasma contaminations. 
To count the cells, old medium was removed from the flask and the cells were detached using trypsin 
(Thermo Fisher, Waltham, MA, USA). An equal volume of medium was used to neutralize the trypsin 
once the cells were fully in suspension, as monitored under an inverted microscope. Cells were 
centrifuged gently to a pellet (1,500 rpm, 5 min, 25 °C) and resuspended in fresh medium. Then, 10 
µL cells were mixed with 10 µL trypan blue stain to stain dead cells (0.4%, Thermo Fisher) and 
counted using the Countess II (Thermo Fisher). 
4.12. MTT Reduction Assay 
Aβ40 oligomers (5 or 10 µM in monomer equivalents, as indicated) were incubated in the absence 
and presence of 20:1 to 5:1 molar ratios of the designed antibodies in cell culture medium for 1 h at 
37 °C under shaking conditions, and then added to the cell culture medium of SH-SY5Y cells seeded 
in 96-well plates for 24 h. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay was performed as previously described [63,64]. 
4.13. Statistics and Data Availability 
Statistical analyses were performed in GraphPad Prism 8 (GraphPad Software, La Jolla, CA, 
USA). All error bars denote standard error of the mean (SEM). One-way ANOVA was used for 
multiple comparisons as a function of increasing concentration of DesAbs relative to oligomers 
incubated in buffer or cell culture medium (with Bonferroni’s multiple comparisons test). 
Comparisons between untreated cells and oligomer-exposed cells were performed using an 
unpaired, two-tailed Student’s t-test. p < 0.05 was accepted as statistically significant. Data are 
available from the authors upon request. 
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Abbreviations 
Aβ amyloid-β peptide 
Aβ40 40-residue form of the amyloid-β peptide 
Aβ42 42-residue form of the amyloid-β peptide 
AD Alzheimer’s disease 
AFM atomic force microscopy 
ANS 8-anilinonapthalene-1-sulfonic acid 
DesAb designed antibody 
HFIP hexafluoroisopropanol 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
SEM standard error of the mean 
SLS static light scattering 
ThT thioflavin T 
TRO trodusquemine 
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